About 354,995 results

Concomitant disease should be considered when treating progressive glaucoma

Jan 20th, 2022 - WAIKOLOA, Hawaii — Ophthalmologists should consider co-management of other diseases when treating progressive glaucoma, according to a speaker here. “I think that we need to remind ourselves, even as we rush through clinic, to think about the linkage to common disease that puts the optic nerve at risk,” Jeffrey L. Goldberg, MD, PhD, said at Hawaiian Eye 2022. To aid with co-management, he said,...

Several pathways under investigation for dry AMD treatment

Jan 18th, 2022 - WAIKOLOA, Hawaii — Several pathways are under investigation for the treatment of dry age-related macular degeneration, according to a presentation at Retina 2022. “The big issue for us researchers is we don’t have a good animal model to test anything,” Peter K. Kaiser, MD, said. “We don’t have preclinical models that inform us if a drug is going to work or not because the animal that we use are...

Effect of a test-and-treat approach to vitamin D supplementation on risk of all cause acute respiratory tract infection and covid-19: phase 3 randomised controlled trial (CORONAVIT)
BMJ Jolliffe D A, Holt H et. al.

Sep 7th, 2022 - The covid-19 pandemic has refocused attention on strategies to prevent acute respiratory tract infection. Although vaccination against SARS-CoV-2 represents the mainstay for disease control, its effectiveness at a global level is compromised by factors such as cost, availability, vaccine hesitancy, vaccine failure, and vaccine escape.123 Complementary, low cost approaches to enhance immunity to...

US CDC announces major changes after criticism of its responses to covid-19 and monkeypox
BMJ Tanne JH.

Aug 23rd, 2022 - The US national public health agency, the Centers for Disease Control and Prevention (CDC), will make major changes to its structure and systems in the light of a review of its emergency response to the covid-19 pandemic.

Single Cell RNA-seq Identifies Major Shifts in Myeloid Cells in Dermatomyositis Skin and Peripheral Blood Compared to Systemic Lupus
Grace Hile, Feiyang Ma, Amanda Victory et. al.

Nov 14th, 2022 - Background/Purpose: Skin disease in dermatomyositis (DM) is relapsing and often refractory to treatment, reflecting a lack of understanding of the mechanisms driving skin inflammation. DM rashes mimic cutaneous lupus erythematosus (CLE), and are frequently challenging to differentiate, particularly if disease is limited to the skin. Distinction is important, as systemic manifestations and progn...

Interferon Alpha Promotes Ultraviolet Light-Mediated Keratinocyte Apoptosis in a Caspase-8 Dependent Manner via Upregulation of Interferon Regulatory Factor 1
Shannon Estadt, Mehrnaz Gharaee-Kermani, Bin Xu et. al.

Nov 14th, 2022 - Background/Purpose: Systemic lupus erythematosus (SLE) is a chronic autoimmune disease characterized by enhanced sensitivity to ultraviolet radiation (UVR). UVR can trigger cutaneous and systemic disease flares, yet mechanisms driving these responses are not yet fully characterized. Type I interferons (IFNs) are overexpressed in non-lesional SLE skin compared to healthy control skin and promote...

In Utero Exposure to Hydroxychloroquine Does Not Associate with Ocular Toxicity as Assessed by Optical Coherence Tomography Five Years After Birth
Peter Izmirly, Mala Masson, Michael Marmor et. al.

Nov 14th, 2022 - Background/Purpose: The preventive approach to congenital heart block with hydroxychloroquine (HCQ) [PATCH] study supported the efficacy of HCQ to reduce the recurrence rate of cardiac disease. This study considered whether the drug had any effects upon the retinal development of these children, examined 5 years later. Methods: Mothers in the PATCH study were treated with HCQ 400mg daily from 1...

Comparing the Safety and Effectiveness of Methotrexate, TNF and IL6 Inhibitors for the Treatment of Checkpoint Inhibitor Arthritis
Anne Bass, Noha Abdel-Wahab, Pankti Reid et. al.

Nov 14th, 2022 - Background/Purpose: Immune checkpoint inhibitor associated arthritis (ICI-A) affects ∼4% of ICI-treated cancer patients and often persists. Given its long duration, it is important to identify effective treatments that do not interfere with cancer responses. However, there are no studies comparing the safety or effectiveness of disease modifying anti-rheumatic drugs (DMARDs) for this condition....

Hydroxychloroquine Dosing Less Than 5 Mg/kg/day Leads to Increased Hospitalizations for Systemic Lupus Erythematosus Flares
Jacquelyn Nestor, Christian Mancini, Baijun Zhou et. al.

Nov 14th, 2022 - Background/Purpose: Hydroxychloroquine (HCQ) is the backbone of SLE therapy, due to its benefits on increasing survival and decreasing lupus flares. In 2011, ophthalmology guidelines recommended limiting HCQ dosing to ≤6.5mg/kg of ideal body weight to reduce the risk of retinopathy; in 2016 updated guidelines recommended using ≤5mg/kg of actual body weight. For many patients, these guidelines r...

Voclosporin for Lupus Nephritis: Assessment of Long-Term Safety and Efficacy Including Renal Outcome over Three Years of Treatment in the Phase 3 AURORA 1 and AURORA 2 Studies
Cristina Arriens, Samir Parikh, Lucy Hodge et. al.

Nov 14th, 2022 - Background/Purpose: In the Phase 3 AURORA 1 study, the addition of voclosporin to mycophenolate mofetil (MMF) and low-dose steroids led to significant reductions in proteinuria at one year in patients with lupus nephritis (LN). Here we report on the recently completed AURORA 2 continuation study evaluating voclosporin compared to control in patients treated for an additional two years after AUR...

Efficacy and Safety of Cenerimod in Patients with Moderate to Severe Systemic Lupus Erythematosus (SLE): A Multicenter, Randomized, Parallel-Group, Double-Blind, Placebo-Controlled, Dose-Finding Ph...
Anca Askanase, Ouali Berkani, clélia Cahuzac et. al.

Nov 14th, 2022 - Background/Purpose: Sphingosine-1-phosphate (S1P) regulates lymphocyte egress from lymphoid organs. In an SLE proof-of-concept study, cenerimod—a potent, selective S1P receptor modulator—reduced lymphocyte count and disease activity (measured by a SLEDAI-2K modified to exclude leukopenia [mSLEDAI-2K]) vs placebo (PBO) (Hermann. Lupus Sci Med 2019;6:e000354). The current phase 2 study (CARE) eva...

Association Between Anti-Sjögren Syndrome/Scleroderma Autoantigen 1 (SSSCA1) Antibodies and Cancer in Systemic Sclerosis
Rachel Wallwork, Livia Casciola-Rosen1 and Ami Shah, Johns Hopkins University et. al.

Nov 14th, 2022 - Background/Purpose: We sought to examine the association between anti-Sjögren syndrome/scleroderma autoantigen 1 (SSSCA1) antibody and cancer in systemic sclerosis (SSc). We also describe the frequency of anti-SSSCA1 antibody positivity and associated clinical phenotype in patients with SSc. Methods: We conducted a case-control study using data from 210 patients with SSc and cancer, and 205 SS...

Association of Dermatomyositis with Cardiovascular Disease: A Case-Control Study in the All of Us Research Program
Jill Shah, Keya Shah, Daniel Mazori et. al.

Nov 14th, 2022 - Background/Purpose: Previous studies on the association of dermatomyositis (DM) with cardiovascular (CV) disease have used combined idiopathic inflammatory myositis cohorts, included only non-United States (US) cohorts, included only inpatients, or have not included matched controls. We aimed to describe the burden and timing of CV disease in a demographically and geographically diverse sample ...

Safety Profile of Hydroxychloroquine in a Large Cohort of Rheumatology Patients Within the US Department of Defense Military Healthcare System
Toni Rush, Rachel Robbins, Angelique Collamer2 and Jess Edison et. al.

Nov 14th, 2022 - Background/Purpose: Hydroxychloroquine (HCQ) is a well-established conventional synthetic DMARD for many rheumatologic conditions. While generally believed to be safe, HCQ use is associated with a wide range of adverse effects with little knowledge of their true frequency. We set out to define the incidence and estimate the risk of known adverse events utilizing a large longitudinal database. M...

Medication Cost Concerns and Disparities in Patient-reported Outcomes Among a Multiethnic Cohort of Patients with Lupus
Alfredo Aguirre, Kimberly DeQuattro, Patricia Katz et. al.

Nov 14th, 2022 - Background/Purpose: Medication cost concerns are associated with nonadherence and poor outcomes in the general population. Prior research has described medication cost concerns in up to one-fifth of patients with systemic lupus erythematosus (SLE), but little is known about the relationship between these concerns and relevant health outcomes. In a multiethnic cohort of patients with SLE, we ass...

Vaccine Uptake in Women with Systemic Lupus Erythematosus (SLE) in a Large Urban Teaching Hospital Serving a High-Risk Population
J. Patricia Dhar, Forsythe Hannah, Louis Saravolatz3 and Susanna Szpunar et. al.

Nov 14th, 2022 - Background/Purpose: Infections are a major cause of morbidity & mortality in patients with systemic lupus erythematosus (SLE), including vaccine-preventable infections. SLE patients are considered to be immunocompromised & thus fall into the Advisory Committee on Immunization Practice’s (ACIP) immunosuppressed category. Vaccines for influenza, pneumococcus, pertussis, varicella, & HPV are safe ...

Does Ancestry Influence Primary Sjögren’s Syndrome Phenotype or Severity?
Maxime Beydon, Marie Dulin, Raphaèle Seror et. al.

Nov 14th, 2022 - Background/Purpose: It is well established that in systemic lupus erythematous (SLE), disease burden is higher in patients from African ancestry (AA) than in Caucasian patients. Although primary Sjögren’s syndrome (pSS) and SLE vary by their clinical presentation, they share common pathogenic mechanisms. Our objectives were to compare demographic and biological parameters as well as disease act...

Serum and Tear Autoantibodies from nor Mice as Potential Diagnostic Indicators of Local and Systemic Inflammation in Sjögren’s Syndrome
Shruti Singh Kakan, Yaping Ju, Maria Edman2 and Sarah Hamm-Alvarez et. al.

Nov 14th, 2022 - Background/Purpose: Sjögren’s Syndrome (SS) is an autoimmune disease characterized by infiltration of lymphocytes into lacrimal (LG) and salivary (SG) glands and their concurrent loss of tear and saliva production, respectively, as well as the development of systemic symptoms. Diagnosis of SS takes ~3 years, due in part to manifestation of symptoms that overlap with other autoimmune diseases. R...

Achieving Increasingly Stringent Clinical Disease Control Criteria Is Associated with Greater Improvements in Patient-Centric Measures of Physical Function and Pain in Patients with Active PsA: 16-...
Jessica Walsh, Laura Coates, Philip J Mease et. al.

Nov 14th, 2022 - Background/Purpose: Examine the association between achieving increasingly stringent clinical disease control criteria and patient-centric measures of physical function and pain in patients with PsA, using data from BE OPTIMAL and BE COMPLETE. Methods: BE OPTIMAL (NCT03895203) and BE COMPLETE (NCT03896581) were phase 3 studies of bimekizumab (BKZ) in patients with active PsA who were bDMARD-naï...

Stringent Disease Activity Control at 2 Years Across Psoriatic Arthritis Domains Irrespective of Baseline Characteristics in Patients Treated with Guselkumab: Post Hoc Analysis of a Phase 3, Random...
Christopher Ritchlin, Philip J Mease, Wolf-Henning Boehncke et. al.

Nov 14th, 2022 - Background/Purpose: Guselkumab (GUS) is associated with robust and sustained improvement in PsA signs and symptoms in subgroups of patients (pts) pooled from the phase 3 DISCOVER-1 and DISCOVER-2 (D2) trials, across a variety of baseline (BL) pt characteristics through 11, and 2 years (D2 only)2. In this post-hoc analysis using D2 data, we evaluated the efficacy of GUS in inducing long-term (W1...